UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
May 14, 2018
(Exact name of registrant as specified in its charter)
New Jersey | I-3215 | 22-1024240 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
732-524-0400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 Regulation FD Disclosure
On April 17, 2018, Johnson & Johnson furnished supplemental sales information related to the Cerenovus business. The 2016 sales information below has been revised to reclassify $156 million from Orthopaedics to Interventional Solutions.
Johnson & Johnson | |||||||||||
Supplemental Sales Information | |||||||||||
(Dollars in Millions) | |||||||||||
Prior quarter amounts have been reclassified to conform to current quarter product disclosure | |||||||||||
2016 | 2017 | ||||||||||
Full Year | Q1 | Q2 | Q3 | Q4 | |||||||
MEDICAL DEVICES SEGMENT (1) | |||||||||||
INTERVENTIONAL SOLUTIONS (2) | |||||||||||
US | $ | 1,031 | 279 | 285 | 279 | 305 | |||||
Intl | 1,024 | 270 | 288 | 274 | 316 | ||||||
WW | 2,055 | 549 | 573 | 553 | 621 | ||||||
ORTHOPAEDICS (2) | |||||||||||
US | 5,438 | 1,359 | 1,367 | 1,308 | 1,370 | ||||||
Intl | 3,690 | 916 | 926 | 896 | 916 | ||||||
WW | 9,128 | 2,275 | 2,293 | 2,204 | 2,286 | ||||||
SPINE & OTHER (2) | |||||||||||
US | 2,152 | 513 | 533 | 495 | 512 | ||||||
Intl | 1,522 | 370 | 382 | 376 | 344 | ||||||
WW | $ | 3,674 | 883 | 915 | 871 | 856 | |||||
(1) Quarterly data unaudited | |||||||||||
(2) All sales related to the Cerenovus business were reclassified to Interventional Solutions (previously referred to as Cardiovascular); The | |||||||||||
Cerenovus business includes the Codman Neurovascular business as well as the recent acquisitions of Neuravi and Pulsar (previously | |||||||||||
included in Spine & Other in Orthopaedics). | |||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Johnson & Johnson | |||
(Registrant) | |||
Date: May 14, 2018 | By: | /s/ Ronald A. Kapusta | |
Ronald A. Kapusta Controller (Principal Accounting Officer) | |||